RedHill Biopharma Ltd RDHL Financial and Strategic SWOT Analysis Review [Report Updated: 17102017] Prices from USD $125

14:10 EST 14 Nov 2017 | BioPortfolio Reports

RedHill Biopharma Ltd RDHL Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


RedHill Biopharma Ltd RedHill is a biopharmaceutical company that develops and commercializes small molecule therapeutics in the areas of gastroenterology, oncology and inflammation. The company's commercial product portfolio consists of gastrointestinal therapeutics for acute enterocolitis and irritable bowel syndrome IBS, and chronic diarrhea and loose stools. It is investigating its pipeline candidates for the treatment of gastrointestinal and inflammatory diseases that include helicobacter pylori infection, crohn's disease, multiple sclerosis, pancreatic cancer, and migraine. RedHill works in collaboration with various pharmaceutical companies to inlicense and commercialize its products in the US. The company has offices in Israel and the US. RedHill is headquartered in Tel Aviv, Israel.

RedHill Biopharma Ltd Key Recent Developments

Aug 10,2017: RedHill Biopharma Provides 2017 SemiAnnual Business Update

Jul 25,2017: RedHill Biopharma Reports 2017 Second Quarter Financial Results

May 03,2017: RedHill Biopharma Reports 2017 First Quarter Financial Results

Mar 29,2017: RedHill Biopharma: Notice of Annual General Meeting of Shareholders

Feb 23,2017: RedHill Biopharma Reports 2016 Fourth Quarter and FullYear Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: RedHill Biopharma Ltd RDHL Financial and Strategic SWOT Analysis Review [Report Updated: 17102017] Prices from USD $125


More From BioPortfolio on "RedHill Biopharma Ltd RDHL Financial and Strategic SWOT Analysis Review [Report Updated: 17102017] Prices from USD $125"

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...